Exoskeletons

Grader A: partial

Ekso, ReWalk and others are FDA-cleared; EksoNR is in about 375 rehabilitation centres worldwide (300+ units in 30 countries by 2021). Routine niche use; no evidence of 5% of rehab facilities or patients globally. US inpatient rehab share might approach 5%, so this is uncertain.

Test: D37 health: share of relevant patients, providers or procedures using it by 2022 (hit >=5%; partial <5% real use by 2022 or 5% in 2023-2025; miss no real use by 2025); relevant: rehabilitation facilities/patients

• Ekso Bionics (2025): EksoNR used in over 375 rehab centres worldwide
• Ekso Bionics nabs FDA exoskeleton clearance for multiple sclerosis rehabilitation (2022): Rehab exoskeleton cleared for more indications

Grader B: partial

Medical exoskeletons (ReWalk FDA 2014, Ekso, Indego, HAL) are in routine use in rehab centres, but volumes are small: Ekso, the leading clinical vendor, booked only 100 devices in all of 2022 on $12.9M revenue. Real niche use; no evidence of 5% patient share.

Test: D37 health: >=5% of relevant rehabilitation facilities or patients (SCI, stroke) use exoskeletons by 2022 = hit; real use below 5% = partial; none by 2025 = miss.

• Ekso Bionics Reports Fourth Quarter and Full Year 2022 Financial Results (2023-02): 100 EksoHealth devices booked in 2022; revenue $12.9M: small clinical installed base.